期刊文献+

奥曲肽对伊立替康化疗后迟发性腹泻小鼠肠黏膜损伤的治疗作用 被引量:10

Preliminary study of treatment of octreotide on Irinotecan induced delayed diarrhea intestinal in mice
下载PDF
导出
摘要 目的:观察和探索奥曲肽对伊立替康化疗后迟发性腹泻小鼠肠黏膜损伤的治疗作用。方法:健康昆明小鼠30只,随机分成3组:A组:CPT-11致小鼠腹泻奥曲肽治疗组;B组:CPT-11致小鼠腹泻对照组;C组:腹腔注射等量生理盐水作为空白对照。观察迟发性腹泻发生情况,实验开始后第9天将小鼠处死,取小肠及结肠组织。光镜下根据Chiu标准对肠黏膜损伤程度进行分级。结果:与对照组相比,治疗组小鼠伊立替康引起的迟发性腹泻症状明显减轻,肠黏膜损伤程度亦减轻(P<0.05)。结论:奥曲肽可以对伊立替康引起的迟发性腹泻起到一定程度的治疗作用。 Objective:To observe the treatment effectiveness of mucositis of Irinotecan induced delayed diarrhea in mice.Methods:Thirty healthy Kunming mice were randomized into 3 groups: Group A: experimental group of octreotide therapy;Group B:control group of CPT-11 induced diarrhea;Group C:injection of physiological saline as control group.To observe the condition of delayed-onset diarrhea,sacrifice the mice on the 9th day,collect the small intestines and colons and evaluate the mucositis according to Chiu criteria under light microscope.Results:Octreotide could release the symptom of CPT-11 induced delayed-onset diarrhea compared with the control group,mice of CPT-11 induced diarrhea in octreotid treatment group release diarrhea symptom,the score decreased obviously and the condition of weight loss comes to alleviation.(P0.05).Octreotide could improve the injuries of intestinal mucosa caused by CPT-11 induced delayed-onset diarrhea.Compared with the control group,mice of CPT-11 induced diarrhea in octreotide treatment group alleviated intestinal mucositis(P0.05).Conclusion:To some extent,octreotide could treat irinotecan induced delayed-onset diarrhea and alleviate intestine and colon mucositis.
出处 《现代肿瘤医学》 CAS 2013年第7期1436-1440,共5页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(编号:30900384)
关键词 伊立替康(CPT-11) 迟发性腹泻 肠黏膜损伤 奥曲肽 irinotecan(CPT-11) delayed-onset diarrhea intestinal mucositis octreotide
  • 相关文献

参考文献4

二级参考文献43

共引文献21

同被引文献133

  • 1陈仲庚.艾森克人格问卷的项目分析[J].心理学报,1983,15(2):211-218. 被引量:380
  • 2Saif MW. Advancements in the management of pancreatic cancer [ J]. J Pancreas,2013,14(2) :112 -118.
  • 3Stomiolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine:resuhs for o- ver 3000 patients with panereatic carcinoma [ J]. Cancer, 1999,85 (6) :1261 - 1268.
  • 4Ioka T, Katayama K, Tanaka S, et al. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post - marketing surveillance in Japan [J]. Jpn J Clin 0ncol,2013,43(2) :139 - 145.
  • 5Giuliani F, Di Maio M, Colucei G, et al. Conventional chemotherapy of advanced pancreatic cancer [ J]. Curr Drug Targets,2012, 13 (6) :795 -801.
  • 6Colucci G, Labianca R, Di Costanzo F. Randomized phase III trial of gemcitabine plus cisplatin compared with single - agent gemcit- abine as first - line treatment of patients with advanced pancreatic cancer:the GIP-1 study[J]. J Clin Oncol,2010,28(10) :1645 - 1651.
  • 7Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine - based combination therapy in the management of advanced pancreatic cancer: a meta - analysis of randomised trials [ J ]. Eur J Cancer, 2013,49(3) :593 -603.
  • 8Hidalgo M. Pancreatic cancer [ J ]. N Engl J Med,2010,362 ( 17 ) : 1605 - 1617.
  • 9Chan MM, Mengshol JA. Octreotide:a drug often used in the criti- cal care setting but not well understood [ J ]. Chest,2013,144 (6) : 1937 - 1945.
  • 10Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of soma- tostatin [ J ]. Mol Cell Endocrino1,2008,286 ( 1 - 2 ) : 230 - 237.

引证文献10

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部